Navigation Links
VeriMed Introduces RADAR(SM): The First Patient Risk Assessment Empowering Pain Physicians To Identify Patients Who May Abuse Or Divert Prescription Drugs
Date:12/3/2013

CHARLOTTE, N.C. and NEW YORK, Dec. 3, 2013 /PRNewswire/ -- VeriMed, a company that has developed technologies to create a safer and more transparent supply chain for controlled substances, today announced the launch of its Risk Assessment of Diversion and Aberrancy (RADARSM), a psychometric assessment that evaluates a patient's risk of abusing or diverting (i.e. selling) prescription medication.

Historically, pain physicians have used assessments that have focused mainly on a patient's likelihood to abuse controlled substances but not their likelihood to exhibit deceptive or manipulative behavior – characteristics that VeriMed believes are at the heart of diversion. RADARSM identifies three specific diversion classifications and six aberrancy categories, providing the physician with a broad baseline of critical information prior to the patient entering the examination room.

"There is a prescription drug epidemic in the U.S., and doctors have become increasingly exposed to the liability of prescribing medication to patients who will abuse and/or divert medication," said Philip E. Gaucher Jr., founder and CEO, VeriMed. "RADARSM gives physicians a picture of a patient's relationship with their medication, offering vital patient information prior to the physician writing a prescription."

"RADARSM provides a snapshot of a patient's mental health, helping doctors validate those patients who are good candidates for pain medication and are perhaps less likely to abuse or divert prescription drugs. By helping reduce exposure to liability, RADARSM allows physicians to focus on providing the best possible care rather than spending time attempting to figure out whether a patient is being truthful regarding his or her needs," said Dr. Michael Trombl
'/>"/>

SOURCE VeriMed
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Konica Minolta Introduces Hand-Held, Real-Time Ultrasound for Use at the Point of Care
2. Smith & Nephew introduces powerful new e-learning platform
3. Kimberly-Clark* Introduces New KimVent* MICROCUFF* Subglottic Suction Endotracheal Tube
4. Smith & Nephew Introduces Advanced Biocomposite Material for Use in Arthroscopic Surgery
5. NxStage Medical Introduces New Products at 2013 American Society of Nephrology Meeting
6. CA BOTANA Introduces SEA ENZYME CALIFORNIA BOTANICAL HAIR SERUM
7. ViGene Biosciences Introduces Worlds Largest Collection of Pre-Made Human Full-Length cDNA ORF and miRNA Adenoviruses
8. Global Vision Introduces New High-Speed Booklet Inspection Technology
9. HOPA Introduces Scope Of Hematology/Oncology Pharmacy Practice
10. RF Technologies Introduces New CodeWatch Designs for Wandering Management Solution
11. Elsevier Introduces SimChart for the Medical Office, a Hands-on EHR to Teach Medical Assistant Students Electronic Documentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014 STAAR Surgical Company (NASDAQ: ... of implantable lenses and delivery systems for the eye ... 4, 2014 of $20.0 million, a 10% increase over ... On a constant currency basis, revenues grew 11% during ... quarter of 2013.  The effect of foreign currency exchange ...
(Date:7/31/2014)... Inc. (NYSE: RMD ) today announced results for ... 30, 2014.  Revenue for the quarter was $415.2 million, flat ... percent decrease on a constant currency basis). Net income was ... quarter ended June 30, 2013. Diluted earnings per share for ... to the quarter ended June 30, 2013.  ...
(Date:7/31/2014)... 31, 2014 Xencor Inc. (NASDAQ: ... engineered monoclonal antibodies for the treatment of autoimmune ... reported financial results for the second quarter ended June ... business highlights. "In the second quarter, ... Society 2014 International Conference (ATS) demonstrating three novel ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6
... Oncomine and Oncomine Concepts Map Integral in Expression and Association ... ... Building on an earlier study,that used Oncomine(TM) to identify ETS-fusion proteins ... identification of,four additional classes of ETS rearrangements in prostate cancer, each of,which ...
... ... Annually, CAMBRIDGE, Mass., Aug. 2 ... trial of Mozobil(TM),(plerixafor) has successfully met its primary and secondary endpoints,demonstrating positive ... non-Hodgkin,s lymphoma. The combined strength of these two trials -- in ...
Cached Medicine Technology:Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications 2Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 2Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 3Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 4Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 5Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 6Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint 7
(Date:8/1/2014)... 01, 2014 On Monday, June 30th, ... User Symposium in San Francisco, CA. Now in its ... JW Marriott Union Square hotel. , “We are excited ... to speed with ACA compliance issues,” Quirk Healthcare Foundation ... symposium provides attendees guidance with NextGen implementation and use, ...
(Date:8/1/2014)... Alan Mozes HealthDay Reporter ... country, barbershops serve as a time-honored destination for a good ... whether barbershops might also be the spot to tackle an ... In a novel partnership, the U.S. Centers for Disease ... Health (MSDH), enlisted the help of barbershop staff to both ...
(Date:8/1/2014)... The North America Endpoint Security Market report defines and ... with analysis and forecast of revenue. This market is ... to $4.77 billion by 2019, at a CAGR of ... TOC of the North America Endpoint Security Market report ... It also provides a glimpse of the segmentation in ...
(Date:8/1/2014)... 1, 2014 The Cardiovascular Research Foundation (CRF) ... investigations that will be presented at next month,s ... the world,s premier educational meeting specializing in interventional ... 17, 2014 at the Walter E. Washington Convention ... presented at TCT often direct the course of ...
(Date:8/1/2014)... NY (PRWEB) August 01, 2014 ... The company develops biomarkers. Its products include CytoSure ... ISCA +SNP Array, CytoSure ISCA UPD array, CytoSure ... v2 array. OGT offers services, such as targeted ... RNA-Seq service, miRNA analysis, gene expression analysis, cytosure ...
Breaking Medicine News(10 mins):Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 2Health News:Barbershops Join Fight Against High Blood Pressure in Black Men 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 2Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 3Health News:CRF announces late-breaking trials and first report investigations for TCT 2014 4Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 2Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 3
... SALAAM, Tanzania, April 25 Today is a,great day for ... and a day to,celebrate. We celebrate because of the possibilities ... today by the United,Nations Secretary General His Excellency Ban Ki-Moon, ... initiative is implemented to the,letter, millions of lives will be ...
... Inc. (NYSE:,NTY) (http://www.NBTY.com ), a leading global manufacturer ... web cast the,presentation by Harvey Kamil, President and Chief ... And Restaurant Conference in,New York on Tuesday, April 29, ... cast live on the Company Web,site, http://www.nbty.com ...
... (Nasdaq: THOR ), a world leader in ... restore failing hearts,today announced that it will report ... 2008 on Thursday, May 1., The company ... financial,results and operating activities to all interested parties ...
... and who,s telling the truth , , FRIDAY, April 25 ... window into the soul, but scientists have been reporting ... imperceptible facial expressions -- tell the real story of ... that people have a lot more trouble hiding their ...
... and reduced risk of recurrence during tuberculosis chemotherapy, according ... of The Journal of Infectious Diseases, now available online. ... common before the advent of anti-TB drugs, is no ... low-income countries even though poor nutrition impairs the immune ...
... Inc.,(Nasdaq: SMBL ) will hold its annual meeting ... 2008, at the Teaneck Marriott at Glenpointe, 100,Frank W. ... the close of business on April 2, 2008, are ... come before the meeting., About Smart Balance Inc., ...
Cached Medicine News:Health News:Statement by H.E. Jakaya Mrisho Kikwete, President of the United Republic of Tanzania, and Chairman of the African Union, in Response to UN-SG Call to Action on Malaria 2Health News:NBTY to Webcast Presentation at Lehman Brothers 11th Annual Retail and Restaurant Conference 2Health News:Thoratec Schedules First Quarter 2008 Conference Call, Webcast 2Health News:Fleeting Facial Expressions Reveal Deep Secrets 2Health News:Fleeting Facial Expressions Reveal Deep Secrets 3Health News:Study shows common vitamin and other micronutrient supplements reduce risks of TB recurrence 2
... For Excellent Drainage PLUS Greater Patient ... BLAKE Drains are white, radiopaque silicone drains ... a solid core center. Their other components ... extension tubing and an adapter. The drains ...
Used for percutaneous placement of laparoscopic surgical instruments. Check-Flo® valve provides a secure seal around the instruments to be introduced. Supplied sterile in peel-open packages. Inte...
Used for internal biliary drainage. Supplied sterile in peel-open packages. Intended for one-time use....
Used for common bile duct exploration. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: